Imagine if diagnosing a complex brain disease was as simple as a routine blood test. Instead of waiting a year for a diagnosis, this tool looks for a specific protein in the blood to spot Multiple Sclerosis early. It's like having a high-tech alarm system that catches the problem before it does permanent damage.
Multiple Sclerosis diagnosis currently takes an average of one year and has a 20% misdiagnosis rate. This delay causes irreversible patient damage and creates a €20 billion annual healthcare overcost.
An ELISA-based diagnostic kit for detecting sIFNAR2 levels in serum and a complementary bioinformatic diagnostic algorithm.
If you are a diagnostic company dealing with the lack of specific biomarkers for neurological diseases — this project developed a kit based on a patented recombinant protein that allows for early MS detection via a simple blood test. This enables a faster transition from patient screening to treatment.
If you are a healthcare provider dealing with a 20% misdiagnosis rate in MS cases — this project developed a bioinformatic diagnostic kit that integrates blood results with clinical variables. This reduces the average one-year diagnosis wait time and prevents irreversible patient damage.
If you are an insurer dealing with a healthcare overcost of around €20 B/yr due to MS misdiagnosis — this project developed a fast and cheap blood test. This reduces long-term disability costs by ensuring pharmacological treatment starts earlier.
Based on available project data, the specific price per test is not listed, but the project describes the test as 'cheap' and 'cost-efficient' for clinical use.
Yes, the project objectives specifically included the generation and validation of an industrial prototype to ensure robustness and consistency for market use.
The kit is based on a patented recombinant protein. The project aims to reach distribution and licensing agreements with multinational IVD companies.
The project is performing an international clinical trial to obtain the CE Mark and FDA Approval.
The project period runs from 2023-02-01 to 2025-07-31, indicating the development and validation phase concludes in mid-2025.
The project is led by a single Spanish SME, ALA DIAGNOSTICS SL, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company is directly managing the transition from a patented protein to an industrial kit and seeking licensing deals.
Contact ALA DIAGNOSTICS SL in Spain regarding IVD licensing
Contact us to explore licensing opportunities for this MS diagnostic biomarker.
